• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZENG Huahua,MA Min,SUN Yujie,HU Jiamin,HUANG Debin.Application value of HMGB1-TLR4 signaling pathway and its regulator in anti-hepatic fibrosis[J].Journal Of Pharmaceutical Research,2023,42(6):398-402[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2612times   Download 2607次 QR Code for this article
Scan with your phone!
HMGB1-TLR4信号通路及其调控物在抗纤维化中的应用价值
曾华华,马敏,孙宇杰,胡嘉敏,黄德斌
Font:Larger+|Default|Smaller-
(湖北民族大学医学院,湖北 恩施 445000)
摘要:
肝纤维化(hepatic fibrosis,HF)的病理生理机制非常复杂,目前始终缺乏理想的治疗药物与方法。本文从HMGB1-TLR4的结构、相关因子(TNF-α、IL-1β、IL-6等)与功能(调节NF-κB、激活MAPK等)分析得知,HMGB1-TLR4主要是通过活化HSC和MAPK,并增强NF-κB的促炎因子释放作用而加重HF。故此认为,通过调控高迁移率族蛋白(HMGB1)- Toll 样受体 4(TLR4)信号通路对于减轻HF的发生发展具有重要价值。尽管在现有HMGB1-TLR4调控物中(如TLR4抗体、NF-κB抑制剂,中药汤剂柴芪益肝方、中成药三草颗粒、单味中药黄芪等),其抗HF作用未达到临床期望值,但以HMGB1-TLR4信号通路为路径,筛选抗HF先导化合物(尤其是多成分多靶位互补效应的中药)仍然是今后努力的方向。
关键词:  高迁移率族蛋白  Toll样受体4  肝纤维化
DOI:10.13506/j.cnki.jpr.2023.06.009
基金项目:国家自然科学基金(No.82060745)
Application value of HMGB1-TLR4 signaling pathway and its regulator in anti-hepatic fibrosis
ZENG Huahua,MA Min,SUN Yujie,HU Jiamin,HUANG Debin
(Hubei University for Nationalities, Enshi 445000, China)
Abstract:
The pathophysiological mechanism of hepatic fibrosis (HF) is extremely complex.Up to now,there is no ideal medicine and methodology in hepatic fibrosis treatment.Based on the analysis of the structure,related factors (TNF-α,IL-1β,IL-6, etc.) and the functions (regulation of NF-κB,activation of MAPK, etc.) of HMGB1-TLR4,it can be inferred that HMGB1-TLR4 aggravates the symptoms of HF by activating HSC,MAPK as well as promoting the release of a pro-inflammatory factor of NF-κB.Accordingly,the regulation of the high mobility group protein (HMGB1) -Toll-like receptor 4 (TLR4) signaling pathway is critical in alleviating the occurrence and development of HF.Although the anti-HF effects among the applications of existing HMGB1-TLR4 regulators has not met clinical expectations yet,such as TLR4 antibody,NF-κB inhibitor,Chaiqi Yigan Decoction,Chines herbal medicine Sancao Granule(SCG),Astragalus root,etc.using HMGB1-TLR4 signaling pathway as the pathway and screening for anti-HF lead compounds especially Chinese medicine with complementary effects of multi-component and multi-target sites still remains to be the target of future research.
Key words:  High Mobility Group Box-1Protein(HMGB1)  Toll-like receptor 4(TLR4)  Hepatic fibrosis(HF)  Diagnostic value
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.